Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms
characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of …

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is the second
volume of the 4th Edition of the WHO series on histological and genetic typing of human …

Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic
syndromes (MDS) has not been evaluated in randomized studies. Objective: To evaluate …

Population-based data on patients with MDS are scarce. Here we report the incidence and
prevalence of MDS based on data from the Düsseldorf MDS Registry. Cases in the city of …

The incidence of myelodysplastic syndromes increases with age and a high prevalence of
co-morbid conditions has been reported in these patients. So far, risk assessment in …

Editorials and Perspectives teria. 10 However, both the systems are based on very similar
criteria, in particular with regard to the ranking of bone marrow blasts. When testing the …

Since 2001, chronic myelomonocytic leukemia (CMML) is classified by the WHO as
myeloproliferative/myelodysplastic neoplasm. Herein we tried to better describe CMML …

There is a paucity of epidemiological data on chronic myeloproliferative disorders and
myelodysplastic syndromes (MDS), while subtypes of acute myeloid leukemia (AML) are …

Hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) are rare
hematopoietic disorders characterized by pancytopenia with hypoplastic bone marrow (BM) …